share_log

Virpax Pharmaceuticals | 8-K: VIRPAX PHARMACEUTICALS REPORTS 2024 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS

SEC ·  Aug 13 19:37

Summary by Futu AI

Virpax Pharmaceuticals, Inc., a Delaware-based company specializing in non-addictive pain management and other pharmaceuticals, reported its financial results for the second quarter ended June 30, 2024, on August 13, 2024. The company announced a decrease in general and administrative expenses to $1.5 million from $1.9 million in the same period the previous year, attributed to reduced severance and insurance expenses. Research and development expenses increased to $2.0 million, up from $1.3 million, mainly due to preclinical activities for their lead asset, Probudur. The operating loss for the quarter was $3.5 million, compared to $3.1 million in 2023. As of June 30, 2024, Virpax had cash reserves of approximately $1.9 million. The company also highlighted recent developments, including positive results from a pharmacokinetics and safety study for Probudur, securing $2.8 million from warrant exercises, and regaining compliance with Nasdaq's minimum bid price requirement. Additionally, Virpax completed a $2.5 million secured loan financing, which led to a reorganization of the company's Board of Directors and the repayment of litigation settlement liabilities.
Virpax Pharmaceuticals, Inc., a Delaware-based company specializing in non-addictive pain management and other pharmaceuticals, reported its financial results for the second quarter ended June 30, 2024, on August 13, 2024. The company announced a decrease in general and administrative expenses to $1.5 million from $1.9 million in the same period the previous year, attributed to reduced severance and insurance expenses. Research and development expenses increased to $2.0 million, up from $1.3 million, mainly due to preclinical activities for their lead asset, Probudur. The operating loss for the quarter was $3.5 million, compared to $3.1 million in 2023. As of June 30, 2024, Virpax had cash reserves of approximately $1.9 million. The company also highlighted recent developments, including positive results from a pharmacokinetics and safety study for Probudur, securing $2.8 million from warrant exercises, and regaining compliance with Nasdaq's minimum bid price requirement. Additionally, Virpax completed a $2.5 million secured loan financing, which led to a reorganization of the company's Board of Directors and the repayment of litigation settlement liabilities.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.